AbbVie Inc.’s newly approved drug Mavyret can treat hepatitis C’s six major strains in eight weeks. It’s also a positive steal in the hepatitis C drug world, at $26,400 for a eight-week ...

NORTH CHICAGO, Ill., June 11, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET® (glecaprevir ...

AbbVie's Mavyret will likely gain 15%-20% of the global HCV market by 2019. Gilead's HCV revenue will likely decline $1B-1.5B per year starting in 2019.

Mavyret approved to treat acute hepatitis C in patients, with or without cirrhosis. Eight-week treatment shows 96% cure rate with mostly mild side effects. Tim Melvin’s system has spotted 10X ...

Approval of Mavyret tablets has been expanded to eight-week treatment for treatment-naive patients with chronic hepatitis C and compensated cirrhosis, the U.S. Food and Drug Administration announced.

AbbVie's Mavyret is the first eight-week treatment that has been approved by the U.S. FDA for all the 1-6 known genotypes of the hepatitis C-Virus in non-cirrhotic HCV patients, who are naive to ...

Mavyret is available as 100mg/40mg fixed-dose tablets in a 4-week (monthly) or 8-week carton. Each carton contains 7 daily dose wallets. For more information visit abbvie.com.

Mavyret is the latest drug to treat all six forms of hepatitis C, following Gilead's Epclusa. Earlier drugs generally are limited to patients with just one or a few hepatitis C types or at certain ...

This photo provided by AbbVie shows the drug Mavyret. On Thursday, Aug. 3, 2017, the Food and Drug Administration approved Mavyret to treat all forms of hepatitis C. The drug works in as little as ...

Mavyret, recently approved by the Food And Drug Administration, can cure hepatitis C in eight weeks, at a cost of $26,400. Though still expensive, that's well below the price of other options.

"MAVYRET has treated more than one million patients with HCV, but we recognize that a significant need remains for patients with acute infection," said Roopal Thakkar, M.D., executive vice ...